



18th June 2009

NORGINE GROWS AGAIN IN 2008

- **European firm sees 22nd consecutive year of double digit sales growth**

Norgine, the leading European specialty pharmaceutical company, is pleased to announce that in 2008 its total revenue increased to €240.8m, with net product sales increasing by 5% to €232.8m. On a constant currency basis, Norgine's net product sales increased by just over 10%, achieving 22 consecutive years of double digit sales growth.

"In today's tough economic climate, our continued investment in development programmes and in improving our business skills, quality standards and compliance to the highest industry standards has paid dividends. In 2009, we will grow our existing business while investing in our people, products and programmes," said Peter Stein, Norgine's CEO.

-ends-

If you would like any further information, or to set up an interview, please contact:

Julie Hornby Winfield: Global Corporate Communications Manager
T: +44 (0)1895 826642
E: jhornbywinfield@norgine.com

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a direct presence in all the major European markets. In 2008, Norgine's net product sales were €232.8m, the 22nd year of double-digit growth at constant exchange rates. The company employs over 1,000 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g., MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a new generation of bowel cleansing preparation, KLEAN-PREP[®] for bowel preparation prior to colonoscopy, XIFAXAN[®] for the treatment of traveller's diarrhoea and ORAMORPH[®] for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France.

Norgine's web site www.norgine.com